Widely used:Recently Viewed
Clear All
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$8,798 Mln
P/E Ratio
107.13
P/B Ratio
2.47
Industry P/E
--
Debt to Equity
0.39
ROE
0.02 %
ROCE
1.61 %
Div. Yield
2.94 %
Book Value
16.36
EPS
0.38
CFO
$4,230.17 Mln
EBITDA
$5,475.50 Mln
Net Profit
$1,864.21 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Qiagen N.V. - ADR
| -11.62 | 2.85 | -14.44 | -1.61 | -6.75 | -1.26 | 3.85 |
|
BSE Sensex*
| 1.94 | 3.72 | 5.18 | 9.14 | 11.26 | 21.09 | 11.17 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Qiagen N.V. - ADR
| -12.91 | -10.27 | 5.17 | 56.36 | -1.89 | 11.32 | 10.51 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 4.24 | 517.80 | 26.63 | 3.8 | |
| 43.23 | 2,974.69 | -- | -31.35 | |
| 1.32 | 119.94 | -- | -42.73 | |
| 13.29 | 703.00 | -- | -238.46 |
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and... purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands. Address: Hulsterweg 82, Venlo, Netherlands, 5912 PL Read more
CEO, MD & Member of Management Board
Mr. Thierry Bernard
CEO, MD & Member of Management Board
Mr. Thierry Bernard
Headquarters
Venlo
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Qiagen NV - ADR stood at $ 5,690 Mln as on 31-Dec-24
The share price of Qiagen NV - ADR is $40.48 (NYSE) as of 21-Apr-2025 16:10 EDT. Qiagen NV - ADR has given a return of -6.75% in the last 3 years.
Qiagen NV - ADR has a market capitalisation of $ 8,798 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Qiagen NV - ADR is 107.13 times as on 21-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Qiagen NV - ADR and enter the required number of quantities and click on buy to purchase the shares of Qiagen NV - ADR.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands. Address: Hulsterweg 82, Venlo, Netherlands, 5912 PL
The CEO & director of Mr. Thierry Bernard. is Qiagen NV - ADR, and CFO & Sr. VP is Mr. Thierry Bernard.
There is no promoter pledging in Qiagen NV - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
296
|
|
|
91
|
|
|
76
|
|
|
36
|
| Qiagen N.V. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
2.27
|
|
Operating margin(%)
|
25.21
|
|
Net Margin(%)
|
4.23
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Qiagen NV - ADR was $0 Mln.
$-0.23
(
